Kehrer J P, Biswal S S, La E, Thuillier P, Datta K, Fischer S M, Vanden Heuvel J P
Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas, Austin, TX 78712, USA.
Biochem J. 2001 Jun 15;356(Pt 3):899-906. doi: 10.1042/0264-6021:3560899.
Although MK886 was originally identified as an inhibitor of 5-lipoxygenase activating protein (FLAP), recent data demonstrate that this activity does not underlie its ability to induce apoptosis [Datta, Biswal and Kehrer (1999) Biochem. J. 340, 371--375]. Since FLAP is a fatty-acid binding protein, it is conceivable that MK886 may affect other such proteins. A family of nuclear receptors that are activated by fatty acids and their metabolites, the peroxisome-proliferator-activated receptors (PPARs), have been implicated in apoptosis and may represent a target for MK886. The ability of MK886 to inhibit PPAR-alpha, -beta and -gamma activity was assessed using reporter assay systems (peroxisome-proliferator response element--luciferase). Using a transient transfection system in monkey kidney fibroblast CV-1 cells, mouse keratinocyte 308 cells and human lung adenocarcinoma A549 cells, 10--20 microM MK886 inhibited Wy14,643 activation of PPAR alpha by approximately 80%. Similar inhibition of PPAR alpha by MK886 was observed with a stable transfection reporter system in CV-1 cells. Only minimal inhibitory effects were seen on PPAR beta and PPAR gamma. MK886 inhibited PPAR alpha by a non-competitive mechanism as shown by its effects on the binding of arachidonic acid to PPAR alpha protein, and a dose-response study using a transient transfection reporter assay in COS-1 cells. An assay assessing PPAR ligand-receptor interactions showed that MK886 prevents the conformational change necessary for active-complex formation. The expression of keratin-1, a protein encoded by a PPAR alpha-responsive gene, was reduced by MK886 in a culture of mouse primary keratinocytes, suggesting that PPAR inhibition has functional consequences in normal cells. Although Jurkat cells express all PPAR isoforms, various PPAR alpha and PPAR gamma agonists were unable to prevent MK886-induced apoptosis. This is consistent with MK886 functioning as a non-competitive inhibitor of PPAR alpha, but may also indicate that PPAR alpha is not directly involved in MK886-induced apoptosis. Although numerous PPAR activators have been identified, the results show that MK886 can inhibit PPAR alpha, making it the first compound identified to have such an effect.
尽管MK886最初被鉴定为5-脂氧合酶激活蛋白(FLAP)的抑制剂,但最近的数据表明,这种活性并非其诱导细胞凋亡能力的基础[达塔、比斯瓦尔和凯勒(1999年)《生物化学杂志》340卷,371 - 375页]。由于FLAP是一种脂肪酸结合蛋白,可以想象MK886可能会影响其他此类蛋白。一类由脂肪酸及其代谢产物激活的核受体,即过氧化物酶体增殖物激活受体(PPARs),与细胞凋亡有关,可能是MK886的作用靶点。使用报告基因检测系统(过氧化物酶体增殖物反应元件 - 荧光素酶)评估了MK886抑制PPAR - α、 - β和 - γ活性的能力。在猴肾成纤维细胞CV - 1、小鼠角质形成细胞308和人肺腺癌A549细胞中使用瞬时转染系统,10 - 20微摩尔的MK886可使Wy14,643对PPARα的激活抑制约80%。在CV - 1细胞的稳定转染报告基因系统中也观察到MK886对PPARα的类似抑制作用。对PPARβ和PPARγ仅观察到最小的抑制作用。MK886通过非竞争性机制抑制PPARα,这从其对花生四烯酸与PPARα蛋白结合的影响以及在COS - 1细胞中使用瞬时转染报告基因检测的剂量反应研究中可以看出。一项评估PPAR配体 - 受体相互作用的检测表明,MK886可阻止形成活性复合物所需的构象变化。在小鼠原代角质形成细胞培养中,MK886可降低由PPARα反应基因编码的蛋白角蛋白 - 1的表达,这表明PPAR抑制在正常细胞中具有功能后果。尽管Jurkat细胞表达所有PPAR亚型,但各种PPARα和PPARγ激动剂均无法阻止MK886诱导的细胞凋亡。这与MK886作为PPARα的非竞争性抑制剂发挥作用一致,但也可能表明PPARα并非直接参与MK886诱导的细胞凋亡。尽管已鉴定出众多PPAR激活剂,但结果表明MK886可抑制PPARα,使其成为首个被鉴定具有这种作用的化合物。